|Bid||921,000.00 x 0|
|Ask||922,000.00 x 0|
|Day's Range||921,000.00 - 935,000.00|
|52 Week Range||624,000.00 - 1,047,000.00|
|Beta (5Y Monthly)||0.80|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 19, 2021 - Oct 25, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||1,015,690.00|
Samsung Biologics, a global contract development and manufacturing organization (CDMO), introduced its proprietary technology platform, S-CellerateTM, at the BioProcess International Conference (BPI 2021) to offer clients an integrated and seamless drug development solution resulting in accelerated timelines.
Samsung Biologics (KRX: 207940.KS), the world's leading contract development and manufacturing organization, announced the signing of an MOU today to participate in the Frontier 1.5D initiative to develop a climate risk management model as part of 2050 Carbon Neutral Strategy in response to the ongoing challenges associated with global climate change.
Samsung Biologics (KRX: 207940.KS), the world's leading contract development and manufacturing organization, today announced strong financial results for the second quarter of fiscal 2021.